ClinicalTrials.gg
RecruitingNCT05652439TRIBEUpdated Oct 22, 2026

PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)

An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
25,000
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Started
2022
with 3 others
Observational
9 of 68
5 open now
Registered
59th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is one of 4 that started in 2022, is one of 9 observational ones, and was the 59th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The aim of this Post Authorisation Safety Study (PASS) is to assess the incidence of adverse cardiovascular and cerebrovascular events in COPD patients who are new to inhaled fixed triple therapy (dual bronchodilator plus corticosteroid) administered via Dry Powder Inhaler (DPI) compared to new users of pressurized Metered Dose Inhaler (pMDI).

Data from clinical practice from different European data sources will be collected. The baseline hypothesis is that the DPI is not associated with different risks of the primary and secondary outcomes, compared with pMDI.

Read the detailed description

Non-interventional, multi-country cohort study to assess the incidence of adverse cardiovascular and cerebrovascular events among patients with chronic obstructive pulmonary disease (COPD), exposed to inhaled fixed triple therapy BDP/FF/GB via DPI (drug of interest) or pMDI (comparator).

The study will be conducted based on secondary health data collected (as per clinical practice) retrospectively from seven different European data sources in the following countries: United Kingdom, Germany, The Netherlands, Denmark, Sweden, Norway and Finland.

Patients in the two exposure groups of this Post Authorisation Safety Study (PASS) will be followed for the study outcomes from the start of the exposure until the first occurrence of end of treatment, switch to the other study drug, end of the study period, or censoring. The pre-defined hypothesis is that the DPI is not associated with different risks of the primary and secondary outcomes, compared with pMDI.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • retrospective
  • cardiovascular
  • cerebrovascular
  • triple therapy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include patients diagnosed with COPD, aged 40 years or older. Eligible for inclusion will be patients with new use of single inhaler triple therapy BDP/FF/GB via DPI or pMDI and no use of any single or multi-inhaler triple therapy (including the study drugs) in the previous 90 days.

The source population includes patients who have at least one prescription/dispensation of BDP/FF/GB administered via DPI or pMDI during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with
  • 40 years or older
  • Availability of baseline information for a minimum of 12 months before the index date
  • New users of single inhaler triple therapy BDP/FF/GB via DPI or pMDI

Exclusion criteria

Exclusion Criteria:

  • Single or multi-inhaler triple therapy in the previous 90 days before the index date
  • Prescription of BDP/FF/GP administered via pMDI or DPI or any other single inhaler triple therapy in addition to a study drug on the index date.
  • Hospitalization due to cardiovascular causes in the previous 30 days before the index date.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
25,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fixed triple therapy BDP/FF/GB via DPI

    COPD patients new users of fixed triple therapy BDP/FF/GB administered via DPI formulation according to local clinical practice

    Other: Observational retrospective data collection

  • Fixed triple therapy BDP/FF/GB via pMDI

    COPD patients new users of fixed triple therapy BDP/FF/GB administered via pMDI formulation according to local clinical practice

    Other: Observational retrospective data collection

Interventions

  • OtherObservational retrospective data collection

    Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes

    Also known as: No treatment given

06

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE)

    To assess the incidence of MACEs and compare it between fixed triple therapy BDP/FF/GB via DPI and pMDI formulation. MACEs will be defined as any of the following events: * Myocardial infarction * Stroke (ischemic and haemorrhagic stroke) * Hospitalization due to acute coronary syndrome * Hospitalization due to heart failure

    Time frame: Through study completion, up to 5 years

Secondary outcomes

  1. Incidence of major cardiovascular and cerebrovascular events individually

    To assess the incidence of each of the following events individually: * Myocardial infarction * Cerebrovascular disorders (ischemic and haemorrhagic stroke, transient ischemic attack) * Hospitalization due to acute coronary syndrome * Hospitalization due to heart failure * Arrhythmias (new-sustained supra-ventricular and sustained ventricular) * All-cause death

    Time frame: Through study completion, up to 5 years

07

Study locations

1 of 1 sites recruiting
  • Clinical Practice Research Datalink (CPRD)
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Only aggregated data will be analysed in this study

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2022 (actual). Primary completion is estimated for Mar 2027, 51 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Aug 2026 → Mar 2027 and completion Aug 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 15, 2022
StartActual
Dec 2, 2022
Primary completionEst.
Mar 2027was Aug 2026
CompletionEst.
Mar 2027was Aug 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Mar 2027
Oct 22, 2026
Study completion
Aug 2026→Mar 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Aug 2026→Mar 2027
    Study completion Aug 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05652439
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Dec 2, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Clinical Trial Info
Contact
clinicaltrials_info@chiesi.com
+3905212791
Fabian Hoti
principal investigator · IQVIA Pty Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion